AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option

colorful brain art model
As AriBio's AR1001 slowed cognitive decline in certain Alzheimer's disease patients, the company plans to discuss the results with the FDA. (iStock / Getty Images Plus)

AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial.

In patients with early Alzheimer’s disease, AriBio’s mirodenafil candidate, AR1001, delivered better clinical outcomes than placebo did—but only in a subgroup of patients who were not on any background therapies such as an acetylcholinesterase inhibitor or memantine, according to results from the Polaris-AD trial.

In the overall population, including those receiving other therapies at baseline, the trial missed statistical significance on change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at week 52. The data were shared at the Clinical Trials on Alzheimer Disease conference in Boston. 

The trial is technically positive, as it’s designed with dual primary populations, each with its separate statistical significance bar. AriBio said it plans to discuss the results with the FDA. 

Digging into the readout, among 604 patients in the prespecified monotherapy population, AR1001 performed 0.44 points better versus placebo, with a p-value of 0.0266 meeting the prespecified statistical significance threshold of 0.03. This translated into a 31% slowing of clinical decline, according to AriBio. For the entire trial of 1,535 patients, the treatment difference came in at 0.11 points lower on CDR-SB in favor of AR1001, or a 7% slowing of decline, but the p-value reached 0.4015, failing the prespecified statistical significance bar of 0.02.

“We started developing AR1001 with the goal of creating an oral treatment that could slow Alzheimer’s progression and be practical for patients and care partners to use over the long term,” Jai-Jun Choung, Ph.D., chairman and CEO of AriBio, said in a Nov. 16 statement. “The 31% slowing of clinical decline at one year in the Monotherapy population supports our hypothesis.”

AR1001 showed numerical advantage on secondary cognitive and functional measures in the monotherapy population, including a treatment effect of 1.16 points versus placebo on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 and a 0.7-point difference on the Mini-Mental State Examination.

With the phase 3 readout, the ball is now in Fosun Pharma’s court. The Chinese pharma paid South Korea’s AriBio $60 million in May for an option to potentially in-license AR1001, a PDE5 inhibitor like Viagra, in the U.S., Europe and Japan. Fosun has 90 days after receiving full Polaris-AD data to decide whether to exercise its option, which will trigger up to $180 million in upfront and regulatory milestone payments. 

Originally developed by SK Chemicals Life Science, mirodenafil has been approved in Korea since 2007 for erectile dysfunction. AR1001 uses a lower dose of the drug at 30 mg taken daily. The drug works differently than antibodies such as Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla, which directly target amyloid-beta plaques in the brain. 

By inhibiting PDE5, mirodenafil prevents the breakdown of cyclic guanosine monophosphate (cGMP), which promotes neuron survival and synaptic plasticity. As a brain-penetrant small molecule, the drug can also dilate cerebral blood vessels, potentially improving blood supply to the brain, while theoretically helping the brain clear toxic protein aggregates like amyloid-beta.  

Supporting those mechanisms, the Polaris-AD trial showed that AR1001 increased cerebrospinal fluid (CSF) cGMP levels versus placebo after one year in both the overall and monotherapy populations. CSF p-tau217 results numerically favored AR1001, but no difference in the CSF Aβ42/40 ratio, which evaluates the presence of amyloid plaque, was observed.

It’s difficult to compare AR1001’s data with anti-amyloid antibodies because of different trial designs. Previously, in the phase 3 Clarity AD trial, Leqembi achieved a 0.45-point difference versus placebo on the CDR-SB metric at 18 months, slowing clinical decline by 27%. About 60% of patients in that study were taking symptomatic Alzheimer’s medications at baseline.

Both Clarity AD and Polaris-AD targeted patients with early symptomatic Alzheimer’s disease, although the baseline characteristics of cognitive impairment were different. 

In an interview with Fierce in June, Fosun Pharma’s CEO of the firm's innovative medicines division, Xingli Wang, M.D., Ph.D., highlighted low dropouts from the Polaris-AD trial, as well as a high rollover rate into the trial's extension period, as positive signs.

In a Nov. 16 release, AriBio described AR1001 as “generally well tolerated.” Over the one-year double-blind treatment phase, serious adverse events happened in 10% of patients in the AR1001 arm, versus 9.8% in the control arm. Deaths happened in four (0.5%) of patients receiving AR1001 and two (0.3%) receiving placebo. Adverse events led to discontinuation of study drug in 5.2% of AR1001-treated participants and 1.7% of placebo-treated participants.

“Polaris-AD has given us important phase 3 data, including results in the prespecified monotherapy population, as well as safety data, for a once-daily oral therapy that could offer patients a convenient treatment option,” Wang said in a Nov. 16 statement. “We will remain patient-centered and, based on the complete body of evidence, continue to work closely with AriBio on the full dataset.”

“The CDR-SB finding in the prespecified monotherapy population and the safety profile are encouraging. The secondary endpoints and biomarker findings warrant further evaluation alongside the overall population outcome to understand AR1001’s therapeutic effects in early Alzheimer’s disease,” Sharon Sha, M.D., of Stanford University and principal investigator of Polaris-AD, said in a statement. “The work of Polaris-AD is another step towards filling an unmet need in early Alzheimer’s disease in which patients need more options for treatment.”